Compare CPB & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPB | MMED |
|---|---|---|
| Founded | 1869 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.5B |
| IPO Year | 1994 | 2025 |
| Metric | CPB | MMED |
|---|---|---|
| Price | $22.85 | $19.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 10 |
| Target Price | ★ $26.06 | $22.56 |
| AVG Volume (30 Days) | ★ 5.1M | 1.1M |
| Earning Date | 06-01-2026 | 06-03-2026 |
| Dividend Yield | ★ 7.63% | N/A |
| EPS Growth | ★ 6.35 | N/A |
| EPS | ★ 1.55 | N/A |
| Revenue | ★ $10,253,000,000.00 | $3,102,000,000.00 |
| Revenue This Year | N/A | $15.99 |
| Revenue Next Year | $0.11 | $10.00 |
| P/E Ratio | $14.65 | ★ N/A |
| Revenue Growth | 6.40 | ★ 14.25 |
| 52 Week Low | $19.56 | $10.65 |
| 52 Week High | $34.18 | $20.88 |
| Indicator | CPB | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 53.54 | 63.46 |
| Support Level | $19.93 | $10.68 |
| Resistance Level | $23.45 | N/A |
| Average True Range (ATR) | 0.56 | 0.84 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 70.75 | 63.66 |
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2025 (July year-end), snacks accounted for 43% of its revenue, followed by soup (27%), other simple meals (23%), and beverages (7%). Beyond its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and, most recently, Rao's (a deal that closed in 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.
Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.